SAS Output

13-JUL-2020 6:10

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1619-Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC 1 N 1 Chemotherapy + Atezolizumab 28 29 12 3 0 0 0 07/16/2018 102 32
            29 12 3 0 0 0      
 
    2 Y 2 Surgery 28 18 10 4 2 0 0 07/16/2018    
            18 10 4 2 0 0      
 
    3 Y 3 Maintenance 28 14 7 3 0 0 0 07/16/2018    
            14 7 3 0 0 0      
 
  S1701-Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac 1 Y 1 Ramucirumab + Carbo/Paclitaxel 66 5 4 3 2 2 0 03/20/2019 103 38
        2 Carboplatin + Paclitaxel   2 2 2 0 0 0      
            7 6 5 2 2 0      
 
  S1800A-Non-Match: Ramu + Pembro vs SoC 1 Y 1 Standard of Care (Inv. Choice) 144 61 59 25 13 6 2 05/28/2019 325 161
        2 Ramucirumab + Pembrolizumab   57 54 26 14 6 1      
            118 113 51 27 12 3      
 
  S1827-SCLC, MRI Surveillance +/- PCI 1 Y 1 PCI + MRI brain surveillance 668 1 1 1 1 0 0 05/04/2020 184 83
        2 MRI brain surveillance   4 4 4 4 3 1      
            5 5 5 5 3 1      
 
  S1900A-LOH and/or BRCA: Rucaparib 1 Y 1 Rucaparib 88 64 53 24 5 3 0 04/16/2019 347 165
            64 53 24 5 3 0      
 
  S1900B-RET Fusion: Selpercatinib (LOXO-292) 1 Y 1 Selpercatinib (LOXO-292) 124 2 2 2 1 0 0 04/08/2020 261 110
            2 2 2 1 0 0      
 
  S1900C-STK11: Talazoparib + Avelumab 1 Y 1 Talazoparib plus avelumab 44 17 17 17 9 3 2 02/14/2020 279 126
            17 17 17 9 3 2      
 
  LUNGMAP-NSCLC, Adv, Master 1 Y 1 Tissue Submission   1369 1006 488 221 72 16 02/06/2019 367 188
            1369 1006 488 221 72 16      
 
Yes A081105-ALCHEMIST1, EGFR mut, Erlotinib 1 E Total Registrations   64 9 4 2 0 0 04/01/2015 379 211
            64 9 4 2 0 0      
 
  A151216-ALCHEMIST0 - screening 1 E Total Registrations   813 79 28 7 3 0 12/16/2014 388 220
            813 79 28 7 3 0      
 
  E4512-ALCHEMIST2, ALK mut, Crizotinib 1 E Total Registrations   15 3 1 1 0 0 02/29/2016 393 216
            15 3 1 1 0 0      
 
  EA5163-NSCLC, Immunotherapy +/- 2nd line therapy 1 E Total Registrations   19 16 5 2 1 0 05/30/2019 299 125
            19 16 5 2 1 0      
 
  NRGCC003-SCLC, PCI or HA-PCI 1 E Total Registrations   4 0 0 0 0 0 10/20/2016 237 129
            4 0 0 0 0 0      
 
    2 E Total Registrations   4 0 0 0 0 0 10/20/2016    
            4 0 0 0 0 0      
 
  NRGLU002-LUNG, Limited Met NSCLC, MST vs LCT + MST 1 E Total Registrations   1 1 0 0 0 0 11/06/2019 312 137
            1 1 0 0 0 0      
 
No A151216-ALCHEMIST0 - screening 0 E Total Registrations   825 72 25 7 3 0 12/16/2014 388 220
            825 72 25 7 3 0      
 
  NRGLU005-LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo 1 E Total Registrations   1 1 0 0 0 0 08/16/2019 333 135
            1 1 0 0 0 0      
 

13-JUL-2020 6:10

LUNG Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo 1 Randomization 25-Mar-20
S1929 ESCLC, SLFN11+, Atezolizumab Talazoparib 1 Screening 15-Jun-20
  2 Randomization 15-Jun-20
S1933 NSCLC, Stg II-III, RT + Atezo 1 Initial Registration 15-Jun-20
  2 Consolidation 15-Jun-20